Ascletis Pharma Inc., of Hangzhou, China, said ravidasvir is recommended by the World Health Organization's guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus (HCV) infection as a future pan-genotypic direct-acting antiviral agent. Read More
Ironwood Pharmaceuticals Inc., of Cambridge, Mass., reported second-quarter U.S. net sales of Linzess, as reported by its U.S. collaboration partner, Dublin-based Allergan plc, totaling $192 million, a 14 percent increase compared to the second quarter of 2017. Read More
Kedalion Therapeutics Inc., of Menlo Park, Calif., said it completed a $5 million series A financing led by Lagunita Biosciences. Proceeds will be used to further develop the company's Acustream technology platform through to pilot-scale GMP manufacturing and support advancement of clinical programs. Read More
HONG KONG – China's Hangzhou Qihan Bio Inc. has completed a series A financing to raise $7.8 million for the development of xenotransplantation procedures, engineering pig organs to be transplanted into humans. Read More
Scientists at the Cleveland Clinic Foundation have developed small-molecule inhibitors that inhibited the bacterial enzyme chain responsible for processing choline into trimethylamine-N-oxide (TMAO). Read More
LONDON – Boehringer Ingelheim GmbH (BI) is making its first move into gene therapy via an agreement with a U.K. academic group that has been working since 2001 to develop an inhaled gene therapy for cystic fibrosis. Read More
Paratek Pharmaceuticals Inc. has one hurdle left before its lead candidate, omadacycline, enters the home stretch of getting FDA approval – Wednesday's half-day session with the Antimicrobial Drugs Advisory Committee. Read More
Not all investors caught the drift of Ovid Therapeutics Inc.'s phase II data with OV-101 (gaboxadol) in Angelman syndrome (AS), but CEO Jeremy Levin told BioWorld that insiders rejoiced and the company is moving ahead with the delta-selective GABAA receptor agonist. Read More
Samumed LLC, a small company developing drugs to harness the Wnt pathway to treat multiple conditions, has closed a $438 million equity round at what it said was a pre-money valuation of $12 billion, marking one of the biggest disclosed private company financings of the year to date. Read More
"What you have in this collaboration is two very like-minded, scientifically driven organizations that are coming together to bring very synergistic and complementary technologies to the field of CAR T cells and T-cell-based immunotherapy," said Philip Gregory, chief scientific officer of Bluebird Bio Inc., describing a five-year pact with Regeneron Pharmaceuticals Inc. to discover, develop and commercialize cancer cell therapies. Read More
